- Home
- WAL vs MIRM Comparison
WAL vs MIRM Comparison
Compare WAL & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WAL | MIRM |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.2B |
| IPO Year | 2005 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WAL | MIRM |
|---|---|---|
| Price | $74.99 | $85.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 14 |
| Target Price | $90.81 | ★ $146.29 |
| AVG Volume (30 Days) | ★ 1.2M | 791.5K |
| Earning Date | 10-19-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | 23.13 | ★ 74.59 |
| EPS | ★ 3.99 | N/A |
| Revenue | ★ $135,800,000.00 | $19,138,000.00 |
| Revenue This Year | $12.54 | $33.62 |
| Revenue Next Year | $6.31 | $17.65 |
| P/E Ratio | $18.58 | ★ N/A |
| Revenue Growth | ★ 99.71 | N/A |
| 52 Week Low | $65.82 | $63.23 |
| 52 Week High | $97.23 | $130.00 |
Technical Indicators
Market Signals| Indicator | WAL | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 41.08 |
| Support Level | $73.93 | $73.82 |
| Resistance Level | $84.75 | $98.03 |
| Average True Range (ATR) | 1.74 | 3.95 |
| MACD | -0.09 | 0.19 |
| Stochastic Oscillator | 39.59 | 52.62 |
Price Performance
Historical ComparisonAbout WAL Western Alliance Bancorporation (DE)
Western Alliance Bancorp provides a full spectrum of customized loan, deposit, and treasury management capabilities, including funds transfer and other digital payment offerings. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.